| Q40667688 | A comparative study of parenteral chloroquine, quinine and pyrimethamine-sulfadoxine in the treatment of Gambian children with complicated, non-cerebral malaria |
| Q41923445 | A comparison of amodiaquine and sulfadoxine-pyrimethamine as first-line treatment of falciparum malaria in Kenya |
| Q40621570 | A prospective evaluation of a clinical algorithm for the diagnosis of malaria in Gambian children |
| Q39279849 | A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children |
| Q41931495 | A randomized trial of chloroquine, amodiaquine and pyrimethamine-sulphadoxine in Gambian children with uncomplicated malaria |
| Q41925939 | A trial of Fansidar plus chloroquine or Fansidar alone for the treatment of uncomplicated malaria in Gambian children |
| Q40546247 | Amodiaquine treatment of uncomplicated malaria in children, in an area of chloroquine-resistantPlasmodium falciparumin north-central Nigeria |
| Q35890499 | Analyzing a Potential Drug Target N-Myristoyltransferase of Plasmodium falciparum Through In Silico Approaches |
| Q36652599 | Antimalarial drug therapy: the role of parasite biology and drug resistance |
| Q43945037 | Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania. |
| Q40528088 | Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial |
| Q39118502 | Averting a malaria disaster |
| Q35205935 | Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy |
| Q24812638 | Bone marrow suppression and severe anaemia associated with persistent plasmodium falciparum infection in african children with microscopically undetectable parasitaemia |
| Q37261552 | Burden of cerebral malaria in central India (2004-2007) |
| Q33584826 | CD4 T-cell expression of IFN-γ and IL-17 in pediatric malarial anemia |
| Q40636403 | Changing home treatment of childhood fevers by training shop keepers in rural Kenya |
| Q39028593 | Changing the first line drug for malaria treatment--cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. |
| Q27974073 | Characterization of Plasmodium falciparum co-chaperone p23: its intrinsic chaperone activity and interaction with Hsp90 |
| Q35891386 | Chemotherapy of drug-resistant malaria |
| Q41916761 | Chloroquine and sulphadoxine-pyrimethamine efficacy for uncomplicated malaria treatment and haematological recovery in children in Bobo-Dioulasso, Burkina Faso during a 3-year period 1998-2000. |
| Q33908753 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. |
| Q41924982 | Chloroquine treatment for uncomplicated childhood malaria in an area with drug resistance: early treatment failure aggravates anaemia |
| Q34743292 | Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. |
| Q46154949 | Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range |
| Q34370425 | Clinical algorithm for treatment of Plasmodium falciparum malaria in children |
| Q39287882 | Clinical efficacy of chloroquine in young children with uncomplicated falciparum malaria--a community-based study in rural Burkina Faso |
| Q41192707 | Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements |
| Q36795473 | Clinical signs for the recognition of children with moderate or severe anaemia in western Kenya |
| Q39122722 | Clinical status and implications of antimalarial drug resistance. |
| Q39116082 | Comparative efficacy of chloroquine and sulphadoxine--pyrimethamine in pregnant women and children: a meta-analysis. |
| Q48034649 | Constituents of Picralima nitida display pronounced inhibitory activities against asexual erythrocytic forms of Plasmodium falciparum in vitro |
| Q39322857 | Controlling malaria: challenges and solutions |
| Q32156246 | Drug resistance among malaria and other parasites |
| Q41930911 | Early clinical failures after pyrimethamine-sulfadoxine treatment of uncomplicated falciparum malaria |
| Q41930308 | Economic implications of resistance to antimalarial drugs |
| Q34643183 | Effectiveness of a community intervention on malaria in rural Tanzania - a randomised controlled trial. |
| Q39677595 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study |
| Q39216490 | Efficacy of artesunate plus chloroquine for uncomplicated malaria in children in Sao Tome and Principe: a double-blind, randomized, controlled trial. |
| Q37117352 | Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in Mali |
| Q40618790 | Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. |
| Q91651618 | En-route to the 'elimination' of genotypic chloroquine resistance in Western and Southern Zambia, 14 years after chloroquine withdrawal |
| Q35056857 | Evaluation of chloroquine as a potent anti-malarial drug: issues of public health policy and healthcare delivery in post-war Liberia |
| Q35112361 | Factors contributing to anemia after uncomplicated falciparum malaria. |
| Q34488950 | Five-year tracking of Plasmodium falciparum allele frequencies in a holoendemic area with indistinct seasonal transitions |
| Q41914706 | Genetic markers of resistance to pyrimethamine and sulfonamides in Plasmodium falciparum parasites compared with the resistance patterns in isolates of Escherichia coli from the same children in Guinea-Bissau |
| Q41919272 | Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. |
| Q41916249 | High Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations |
| Q41942907 | High prevalence of molecular markers for resistance to chloroquine and pyrimethamine in Plasmodium falciparum from Zimbabwe |
| Q38927563 | High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. |
| Q38959049 | History and importance of antimalarial drug resistance |
| Q35545447 | History, dynamics, and public health importance of malaria parasite resistance |
| Q28534763 | Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library |
| Q35832081 | Impact of Malaria Control on Mortality and Anemia among Tanzanian Children Less than Five Years of Age, 1999-2010 |
| Q45105262 | Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique |
| Q54121783 | Impact of chloroquine resistance on malaria mortality. |
| Q37133983 | Impact on malaria morbidity of a programme supplying insecticide treated nets in children aged under 2 years in Tanzania: community cross sectional study |
| Q105082384 | Impacts of development and global change on the epidemiological environment |
| Q44874460 | Implementation of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in Kisumu, western Kenya |
| Q40617013 | In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania |
| Q36736817 | In-vivo parasitological response to sulfadoxine-pyrimethamine in pregnant women in southern Malawi |
| Q35013414 | Increasing antimalarial drug resistance in Uganda and revision of the national drug policy |
| Q38884162 | Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? |
| Q47997750 | Intermittent preventive therapy for malaria with monthly artemether-lumefantrine for the post-discharge management of severe anaemia in children aged 4-59 months in southern Malawi: a multicentre, randomised, placebo-controlled trial. |
| Q45105266 | Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria |
| Q39557015 | Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. |
| Q39312681 | Malaria and human immunodeficiency virus infection among male employees of a sugar estate in Malawi |
| Q34999477 | Malaria associated anaemia, drug resistance and antimalarial combination therapy |
| Q40468998 | Malaria control using indoor residual spraying and larvivorous fish: a case study in Betul, central India. |
| Q46597247 | Malaria cure with sulphadoxine/pyrimethamine combination in 12 semi-immune adults from West-Central Africa with high rates of point mutations in Plasmodium falciparum dhfr and dhps genes |
| Q48007457 | Malaria medicines to address drug resistance and support malaria elimination efforts |
| Q36955257 | Malaria research and its influence on anti-malarial drug policy in Malawi: a case study |
| Q34807496 | Malaria: Current status of control, diagnosis, treatment, and a proposed agenda for research and development |
| Q34825627 | Malaria: a rising incidence in the United States |
| Q40718149 | Malarial parasites and antioxidant nutrients |
| Q41927519 | Malarone-donation programme in Africa |
| Q41927152 | Management of severe malarial anaemia in Gambian children |
| Q35880187 | Maternal malaria and perinatal HIV transmission, western Kenya |
| Q35755266 | Media, health workers, and policy makers' relationship and their impact on antimalarial policy adoption: a population genetics perspective |
| Q27000750 | Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems |
| Q33971977 | Modelling a predictable disaster: the rise and spread of drug-resistantmalaria |
| Q34547922 | Modern chemotherapeutic options for malaria |
| Q47852173 | Molecular epidemiology of Plasmodium falciparum antifolate resistance in Vietnam: genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase |
| Q35541782 | Monitoring antimalarial drug resistance: making the most of the tools at hand |
| Q92155904 | Multiple-Strain Malaria Infection and Its Impacts on Plasmodium falciparum Resistance to Antimalarial Therapy: A Mathematical Modelling Perspective |
| Q33893267 | Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data |
| Q41292997 | Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications |
| Q38880836 | Plasmodium falciparum: higher incidence of molecular resistance markers for sulphadoxine than for pyrimethamine in Kasangati, Uganda |
| Q38913536 | Predictors of mortality in Gambian children with severe malaria anaemia. |
| Q47888876 | Prevalence and severity of anemia and iron deficiency: cross-sectional studies in adolescent schoolgirls in western Kenya |
| Q37154392 | Prevalence of malaria, prevention measures, and main clinical features in febrile children admitted to the Franceville Regional Hospital, Gabon |
| Q39589995 | Preventing antimalarial drug resistance through combinations |
| Q44959514 | Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: a randomized controlled trial. |
| Q33889755 | Progressive increase in point mutations associates chloroquine resistance: Even after withdrawal of chloroquine use in India |
| Q35106591 | Quality of malaria case management in Malawi: results from a nationally representative health facility survey |
| Q40604659 | Rapid therapeutic response onset of a new pharmaceutical form of chloroquine phosphate 300 mg: effervescent tablets |
| Q26865357 | Rational approaches to improving selectivity in drug design |
| Q41931287 | Reducing the oral quinine-quinidine-cinchonin (Quinimax) treatment of uncomplicated malaria to three days does not increase the recurrence of attacks among children living in a highly endemic area of Senegal |
| Q36050791 | Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites |
| Q39643675 | Risk factors for malaria in pregnancy in an urban and peri-urban population in western Kenya |
| Q37008611 | Scaling up impact of malaria control programmes: a tale of events in Sub-Saharan Africa and People's Republic of China |
| Q40366944 | Self-medication with chloroquine in a rural district of Tanzania: a therapeutic challenge for any future malaria treatment policy change in the country |
| Q36794819 | Self-treatment of malaria in a rural area of western Kenya. |
| Q41921456 | Sulfadoxine-pyrimethamine for the treatment of Plasmodium falciparum malaria in Gabonese children |
| Q39652433 | Sulfadoxine-pyrimethamine resistance in the rodent malaria parasite Plasmodium chabaudi |
| Q41917325 | Sulphadoxine/pyrimethamine: an appropriate first-line alternative for the treatment of uncomplicated falciparum malaria in Ghanaian children under 5 years of age. |
| Q37261150 | Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective study |
| Q35185058 | Taking stock: provider prescribing practices in the presence and absence of ACT stock |
| Q35937366 | The Blantyre Integrated Malaria Initiative: a model for effective malaria control |
| Q36947762 | The anatomy of a malaria disaster: drug policy choice and mortality in African children |
| Q36463337 | The changing limits and incidence of malaria in Africa: 1939-2009. |
| Q38885343 | The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda |
| Q41945474 | The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis |
| Q37476612 | The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia |
| Q41919429 | Therapeutic efficacy of sulphadoxine/pyrimethamine and susceptibility in vitro of P. falciparum isolates to sulphadoxine-pyremethamine and other antimalarial drugs in Malawian children |
| Q33979170 | Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites |
| Q39587871 | Transfection and malaria |
| Q33981071 | Use of molecular beacons to detect an antifolate resistance-associated mutation in Plasmodium falciparum |
| Q34109430 | Using evidence to change antimalarial drug policy in Kenya |
| Q40924706 | Vitamin E and selenium: contrasting and interacting nutritional determinants of host resistance to parasitic and viral infections |
| Q41917895 | Weekly chloroquine prophylaxis and the effect on maternal haemoglobin status at delivery |
| Q30483555 | World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria |